Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Samer K. Khaled(City Of Hope National Medical Center), Giovanni Martinelli(Istituti di Ricovero e Cura a Carattere Scientifico), Alexander E. Perl(University of Pennsylvania), Siddhartha Ganguly(University of Kansas), Nigel H. Russell, Alwin Krämer(German Cancer Research Center), Hervé Dombret(Délégation Paris 7), Donna E. Hogge(Vancouver General Hospital), Brian A. Jonas(UC Davis Comprehensive Cancer Center), Anskar Y.H. Leung(University of Hong Kong), Priyanka Mehta(University Hospitals Bristol NHS Foundation Trust), Pau Montesinos(Centro de Investigación Biomédica en Red de Cáncer), Markus P. Radsak(University Medical Center of the Johannes Gutenberg University Mainz), Simona Sica(Università Cattolica del Sacro Cuore), Meena Arunachalam(Daiichi Sankyo (United States)), Melissa F. Holmes(Daiichi Sankyo (United States)), Ken Kobayashi(Daiichi Sankyo (United States)), Ruth Namuyinga(Daiichi Sankyo (United States)), Nanxiang Ge(Daiichi Sankyo (United States)), Antoine Yver(Daiichi Sankyo (United States)), Yufen Zhang(Daiichi Sankyo (United States)), Mark J. Levis(Sidney Kimmel Comprehensive Cancer Center)
The Lancet Oncology
June 4, 2019
Cited by 475

Abstract


Related Papers

No related papers found

Powered by citation graph analysis